Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.6.0.2
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (15,803,000) $ (20,184,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 2,032,000 1,503,000
Amortization 343,000 159,000
Provision for bad debts 723,000 413,000
Stock-based compensation 2,016,000 2,834,000
Stock issued for consulting services 75,000 0
Change in fair value of acquisition note payable (152,000) (269,000)
Change in fair value of warrant liability (1,525,000) (35,000)
Amortization of loan guarantee, financing fees and debt issuance costs 12,000 8,000
Loss in equity-method investment 73,000 707,000
Change in working capital components:    
Accounts receivable (5,850,000) (1,662,000)
Other current assets (56,000) (384,000)
Other non-current assets (69,000) (101,000)
Accounts payable, accrued expenses and deferred revenue 355,000 3,114,000
Deferred rent and other (25,000) (33,000)
Net cash (used in) operating activities (17,851,000) (13,599,000)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of fixed assets (490,000) (1,008,000)
Decrease in restricted cash 0 6,000,000
Patent costs (119,000) (137,000)
Cash used in acquisition of Response Genetics 0 (7,495,000)
Net cash (used in) investing activities (609,000) (2,640,000)
CASH FLOWS FROM FINANCING ACTIVITIES    
Principal payments on capital lease obligations (126,000) (83,000)
Payment of equity issuance costs 0 (117,000)
Proceeds from public offerings of equity, net of offering costs 9,962,000 10,353,000
Proceeds from warrant exercises 0 1,000
Proceeds from option exercises 0 23,480
Payment of debt issuance costs 0 (33,000)
Principal payments on notes payable (1,333,000) 0
Net cash provided by financing activities 8,503,000 10,144,000
Net (decrease) in cash and cash equivalents (9,957,000) (6,095,000)
CASH AND CASH EQUIVALENTS    
Beginning 19,459,000 25,554,000
Ending 9,502,000 19,459,000
SUPPLEMENTAL CASH FLOW DISCLOSURE    
Cash paid for interest 333,000 240,000
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES    
Fixed assets acquired through capital lease arrangements 211,000 0
Net tangible assets acquired via acquisition 0 2,843,000
BioServe    
Adjustments to reconcile net loss to net cash used in operating activities:    
Change in fair value of acquisition note payable (152,000) 269,000
Gentris Corporation    
Adjustments to reconcile net loss to net cash used in operating activities:    
Change in fair value of acquisition note payable 0 (207,000)
Response Genetics    
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES    
Value of shares issued as partial consideration to acquire businesses $ 0 $ 5,436,000